M&A / Deals Lilly boosts ADC portfolio with CrossBridge Bio deal BioPharma DiveWorth up to $300 million, the buyout is Lilly s latest of an ADC maker and adds technology for making dual-payload therapies.M&A / DealsOncologyRead full story pharminent April 14, 2026 (Last updated: April 14, 2026) BioPharma Dive Worth up to $300 million, the buyout is Lilly s latest of an ADC maker and adds technology for making dual-payload therapies. M&A / DealsOncologyRead full story Post navigation Previous: Lilly investing billions to prepare for overseas oral GLP-1 launchesNext: With nearly a quarter billion in Q1, J&J targets $100B revenue in 2026 Related Stories M&A / Deals BioMarin spends up to $490m for Alesta’s bone disease candidate pharminent August 19, 2026 M&A / Deals J&J hands lymphoma bispecific CAR T back to AbelZeta pharminent August 17, 2026 M&A / Deals Novo Nordisk and AWS form AI partnership to speed drug discovery pharminent August 17, 2026
